| Dr Laura M Breymann, MD | |
|
333 108th Ave Ne Ste M150, Bellevue, WA 98004-5722 | |
| (425) 454-3300 | |
| (206) 381-3035 |
| Full Name | Dr Laura M Breymann |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 333 108th Ave Ne Ste M150, Bellevue, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336387331 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD60173914 (Washington) | Primary |
| Entity Name | Healthpoint |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831199454 PECOS PAC ID: 9335042886 Enrollment ID: O20040206000245 |
News Archive
Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin's proprietary technology.
Acute kidney injury (AKI) is sudden kidney failure or damage lasting from a few hours to several days. During this time, the kidney's ability to maintain a proper balance of bodily fluids is compromised and causes a buildup of waste products in the blood.
Hazelden, one of the world's largest and most respected private, nonprofit alcohol and drug addiction treatment centers, announced today that it will open a first-of-its-kind collegiate recovery residence called Tribeca Twelve in New York City's Tribeca neighborhood.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
For the first time, scientists at The Scripps Research Institute (TSRI) have solved the structure of the biological machinery used by a common virus to recognize and attack human host cells.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura M Breymann, MD 2101 4th Ave Ste 600, Seattle, WA 98121-2381 Ph: () - | Dr Laura M Breymann, MD 333 108th Ave Ne Ste M150, Bellevue, WA 98004-5722 Ph: (425) 454-3300 |
News Archive
Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin's proprietary technology.
Acute kidney injury (AKI) is sudden kidney failure or damage lasting from a few hours to several days. During this time, the kidney's ability to maintain a proper balance of bodily fluids is compromised and causes a buildup of waste products in the blood.
Hazelden, one of the world's largest and most respected private, nonprofit alcohol and drug addiction treatment centers, announced today that it will open a first-of-its-kind collegiate recovery residence called Tribeca Twelve in New York City's Tribeca neighborhood.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
For the first time, scientists at The Scripps Research Institute (TSRI) have solved the structure of the biological machinery used by a common virus to recognize and attack human host cells.
› Verified 2 days ago
Dr. Steven Yee, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 14505 Bel Red Rd, 100, Bellevue, WA 98007 Phone: 425-283-5080 | |
Martha Riggers, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3080 148th Ave Se, Suite 115, Bellevue, WA 98007 Phone: 425-378-8190 Fax: 425-649-1523 | |
Peter Myles Mcgough, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13231 Se 36th St Ste 110, Bellevue, WA 98006 Phone: 425-957-9000 | |
Dr. Roseanna Lee Perry, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3039 110th Ave Se, Bellevue, WA 98004 Phone: 425-455-5081 | |
Mrs. Janine R Cooley, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1200 112th Ave Ne, Ste C160, Bellevue, WA 98004 Phone: 425-453-1039 Fax: 425-453-8955 | |
Ms. Denise S Kraft, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 112th Ave Ne, Ste C160, Bellevue, WA 98004 Phone: 425-453-1039 Fax: 425-453-8955 | |
Jennifer Lizarraga Richards, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 112th Ave Ne, #b250, Bellevue, WA 98004 Phone: 206-386-9500 Fax: 206-576-3802 |